BIOSOURCE INTERNATIONAL INC
SC 13D/A, EX-5, 2000-09-22
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: BIOSOURCE INTERNATIONAL INC, SC 13D/A, EX-4, 2000-09-22
Next: UNITED INVESTORS GROWTH PROPERTIES II, 8-K, 2000-09-22



<PAGE>

                                                                       EXHIBIT 5

                                   AMENDMENT
                                      TO
                           INVESTOR RIGHTS AGREEMENT

     THIS AMENDMENT (this "Amendment"), dated as of September 18, 2000, by and
among BIOSOURCE INTERNATIONAL, INC., a corporation organized under the laws of
the State of Delaware (the "Company"); GENSTAR CAPITAL PARTNERS II, L.P., a
Delaware limited partnership ("Genstar Capital Partners"); STARGEN II LLC, a
Delaware limited liability company ("Stargen"); RUSSELL D. HAYS, an individual
("Hays"); and GEORGE UVEGES, an individual ("Uveges" and, together with Hays,
the "New Investors" and, together with Hays, Genstar Capital Partners and
Stargen, the "Investors").

                                   RECITALS

     WHEREAS, the Company, Genstar Capital Partners and Stargen are parties to
that certain Investor Rights Agreement dated February 15, 2000 (the "Agreement,"
capitalized terms used herein and not otherwise defined herein shall have the
respective meanings set forth in the Agreement);

     WHEREAS, the Company and Genstar Capital Partners, on the one hand, and the
Company and the New Investors, on the other hand, have entered into certain
purchase agreements dated September 15, 2000 and September 18, 2000,
respectively (collectively, the "Purchase Agreements"), pursuant to which the
Company has agreed, upon the terms and subject to the conditions contained
therein, to issue and sell to Genstar Capital Partners and the New Investors an
aggregate of 351,428 shares of the Company's Common Stock Stock, par value
$0.001 per share (the "Shares"); and

     WHEREAS, in connection with the transactions contemplated by the Purchase
Agreements, the Company and the Investors desire to amend the Agreement to
provide to Genstar Capital Partners and the New Investors certain registration
rights with respect to the Shares under the Securities Act, and applicable state
securities laws.

                                   AGREEMENT

     NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Company and the Investors,
intending to be legally bound, hereby agree as follows:

     1. Amendment to Definitions. Section 1(b) of the Agreement is hereby
amended to read as follows:

        (b) "Registrable Securities" means (i) the shares of Common Stock of the
     Company issued to Genstar Capital Partners and the New Investors pursuant
     to certain purchase agreements dated September 15, 2000 and September 18,
     2000, respectively, by and among the Company and Genstar Capital Partners,
     on the one hand, and the Company and the New Investors, on the other hand,
     and (ii) the shares of Common Stock
<PAGE>

     of the Company issued or issuable to Genstar Capital Partners and Stargen
     upon conversion of the Series B Shares or upon exercise of the Warrants and
     any shares of capital stock issued or issuable, from time to time (with any
     adjustments), as a distribution on or in exchange for or otherwise with
     respect to the foregoing.

          Section 1 of the Agreement is hereby amended to add the following new
subsections:

          (d)  "Investors" shall mean each of Genstar Capital Partners II, L.P.
     ("Genstar Capital Partners"), Stargen II LLC ("Stargen"), Russell D. Hays
     and George Uveges; provided, however, that neither Russell D. Hays nor
     George Uveges shall be deemed to be an "Investor" under Sections 10, 11, 12
     or 13 of this Agreement.

          (e)  "New Investors" shall mean each of Russell D. Hays and George
     Uveges.

     2.   Joinder. The Company and the Investors hereby agree that (i) the New
Investors shall be deemed to be parties to the Agreement; and (ii) Genstar
Capital Partners and the New Investors shall be entitled to all of the rights,
benefits and privileges of Investors, and shall observe all of the obligations
of Investors, under the Agreement with respect to the Shares held by each of
them; provided, however, that none of the New Investors shall be deemed to be an
"Investor" under Sections 10, 11, 12 or 13 of the Agreement, nor shall any of
the New Investors be entitled to any of the rights, benefits or privileges
inuring to the benefit of "Investors" under Sections 10, 11, 12 or 13 of the
Agreement, such rights, benefits and privileges being reserved for the exclusive
benefit of Genstar Capital Partners and Stargen.

     3.   Entire Agreement. This Amendment supersedes the Agreement solely with
respect to the subject matter herein. All terms and provisions of the Agreement
not affected by this Amendment remain binding and enforceable between Investors
and the Company.


                  [Remainder of page intentionally left blank]

                                       2
<PAGE>

          IN WITNESS WHEREOF, the parties have caused this Amendment to be duly
executed as of the date first above written.


                              BIOSOURCE INTERNATIONAL, INC.


                              By: /s/ James Chamberlain
                                  ------------------------------
                                  James Chamberlain
                                  President and Chief Executive Officer


                              GENSTAR CAPITAL PARTNERS II, L.P.

                              By: Genstar Capital LLC
                                  Its General Partner


                              By: /s/ Jean-Pierre L. Conte
                                 ---------------------------
                                  Jean-Pierre L. Conte
                                  Managing Director


                              STARGEN II LLC


                              By: /s/ Jean-Pierre L. Conte
                                 ---------------------------
                                  Jean-Pierre L. Conte
                                  Managing Director


                              /s Russell D. Hays
                              ------------------------------
                              Russell D. Hays


                              /s/ George Uveges
                              ------------------------------
                              George Uveges

                                       3


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission